A Phase II Trial Evaluating The Efficacy Of Radioiodinated Anti-B1 (Anti-CD20) Antibody, Etoposide And Cyclophosphamide Followed By Autologous Transplantation, For Relapsed Or Refractory Non-Hodgkin's Lymphoma.

Trial Profile

A Phase II Trial Evaluating The Efficacy Of Radioiodinated Anti-B1 (Anti-CD20) Antibody, Etoposide And Cyclophosphamide Followed By Autologous Transplantation, For Relapsed Or Refractory Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Iodine-131 tositumomab (Primary) ; Cyclophosphamide; Etoposide
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 31 Jan 2011 Planned End Date changed from 1 Dec 2071 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 27 Dec 2009 Additional lead trial investigator [Ajay Gopal] identified as reported by University of Washington Health Sciences record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top